AGP Picks
View all

CIDP market seen reaching $3.32 billion by 2030

3 hours ago
CIDP market seen reaching $3.32 billion by 2030
By AI, Created 16:30 UTC, Nov 18, 2026, AGP -

The global market for chronic inflammatory demyelinating polyneuropathy is projected to grow from $2.27 billion in 2025 to $3.32 billion by 2030, driven by better diagnosis, broader IVIG use and rising healthcare spending. North America held the largest share in 2025, while the report points to more home-based treatment, remote monitoring and personalized care ahead.

Why it matters: - CIDP is a rare autoimmune disease that causes progressive muscle weakness, numbness and balance problems. - The market’s growth signals more diagnosis, broader treatment access and rising demand for long-term disease management. - The expansion also points to deeper investment in rare-disease care and therapies that reduce side effects.

What happened: - The Business Research Company published its Chronic Inflammatory Demyelinating Polyneuropathy Global Market Report 2026. - The CIDP market is projected to rise from $2.27 billion in 2025 to $2.46 billion in 2026. - That 2025-to-2026 increase reflects an 8.1% compound annual growth rate. - The market is forecast to reach $3.32 billion by 2030, with a 7.8% CAGR from 2026 to 2030. - North America held the largest regional market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report offers a free sample here. - The full report is available here.

The details: - Market growth over the past period was tied to greater awareness of rare autoimmune neuropathies. - Wider access to intravenous immunoglobulin, or IVIG, also supported expansion. - Improved electrodiagnostic testing helped more patients get identified. - More specialized neurology care and better recognition of CIDP subtypes added to demand. - Future growth is expected to come from targeted immunotherapies. - The report cites a stronger focus on lowering treatment side effects. - Remote patient monitoring is expected to gain wider use. - Demand is rising for therapies that can deliver sustained remission. - Investment in rare-disease research is another expected driver. - The report highlights wider use of IVIG as a first-line therapy. - It also points to more personalized treatment protocols and advanced diagnostic methods. - Home-based treatment options and longer-term disease management are listed as key trends.

Between the lines: - Healthcare spending is a major tailwind for the CIDP market. - Higher medical infrastructure investment, expanded insurance coverage and government efforts to improve access are all feeding demand. - More spending can mean earlier diagnosis and access to advanced therapies, which may improve outcomes for patients. - The report cites UK data showing total healthcare expenditure rose 5.6% nominally from 2022 to 2023, after a 0.9% increase the prior year. - That spending trend suggests more resources are flowing into the kinds of treatments and diagnostics that support CIDP care.

What's next: - The market will likely keep shifting toward more targeted and individualized treatment. - Remote monitoring and home-based care could take a larger role in managing CIDP over time. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated trend analysis. - The Business Research Company invites readers to contact its expert team for more information.

The bottom line: - CIDP is moving from a niche rare-disease market toward steadier growth, supported by better diagnosis, more treatment options and stronger healthcare spending.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Europe Daily Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Europe Daily Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.